Agilent's Dako and Merck Partner on Cancer Treatments

Continuing its strategy of developing key partnerships with some of the pharma industry's biggest companies, Denmark-based Dako, Agilent Technologies' (NYSE: A  ) cancer diagnostics division, announced today it has entered into a "master framework agreement" with Merck (NYSE: MRK  ) .

Master framework agreements, as defined by the European Commission, are contracts used to establish the terms and conditions (framework), particularly relating to price and quantity, between one or more parties. Financial terms of the deal between Dako and Merck were not disclosed.

The agreement with Merck calls for Dako to develop "companion diagnostic tests" for cancer-fighting drugs. The companion tests developed will be for oncology drugs in Merck's development pipeline, Dako said. Companion diagnostics, according to Dako, are especially useful in determining the appropriate oncology therapy based on an individual patient's needs.

"With Dako's wide experience in companion diagnostics and its expanded playing field as part of Agilent's Life Sciences and Diagnostics Group, I see great potential in this new agreement," Jacob Thaysen, vice president and general manager for Agilent's diagnostics and genomics division, said in a press release.

Agilent acquired Dako for $2.2 billion in an all-cash deal that closed on July 21, 2012. Since the acquisition, Dako has signed agreements similar to today's Merck deal with Eli Lilly and Pfizer (NYSE: PFE  ) . Dako also has partnerships with Bristol-Myers Squibb and a division of Switzerland-based Roche Holding.



Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2789594, ~/Articles/ArticleHandler.aspx, 9/5/2015 12:30:22 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Tim Brugger

Tim has been writing professionally for several years after spending 18 years (Whew! Was it that long?)in both the retail and institutional side of the financial services industry. Tim resides in Portland, Oregon with his three children and the family dog.

Today's Market

updated 15 hours ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 4:02 PM
A $35.06 Down -0.69 -1.93%
Agilent Technologi… CAPS Rating: ****
MRK $51.59 Down -1.06 -2.01%
Merck & Co., Inc. CAPS Rating: ****
BMY $57.30 Down -1.45 -2.47%
Bristol-Myers Squi… CAPS Rating: ****
LLY $80.32 Down -1.28 -1.57%
Eli Lilly & Co. CAPS Rating: ****
PFE $31.37 Down -0.52 -1.63%
Pfizer CAPS Rating: ****
RHHBY $33.36 Down -0.04 -0.12%
Roche Holding Ltd.… CAPS Rating: *****